[Value of mazindol in Gélineau's disease. Apropos of 10 cases].
Ten narcoleptic patients were treated daily with Mazindol 2-6 mg for 42.2 months (31-63 months). The response was excellent on narcoleptic attacks in 6 and on cataplexy in 7 cases. However, the nocturnal sleep disturbance persisted unchanged. The improvement was poor in 1 case and inexistant in 1 subject. Minor side effects (dry mouth) occurred in 3 cases, and urinary retention obliged to stop the medication in 2 cases.
D000293:Adolescent; D000328:Adult; D002375:Catalepsy / Q000188:drug therapy; D002997:Clomipramine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008454:Mazindol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009290:Narcolepsy / Q000188:drug therapy*; D014555:Urination Disorders / Q000139:chemically induced; D014987:Xerostomia / Q000139:chemically induced
D007211:Indoles; D008454:Mazindol; D002997:Clomipramine
Intérêt du mazindol dans la maladie de gélineau. A propos de 10 observations.